Investor Alert

New York Markets Open in:

Market Pulse Archives

March 19, 2021, 7:49 a.m. EDT

Idera Pharmaceuticals stock plunges after disappointing trial results, prompting analyst downgrade

Watchlist Relevance

Want to see how this story relates to your watchlist?

Just add items to create a watchlist now:

  • X
    Idera Pharmaceuticals Inc. (IDRA)
  • X
    iShares Biotechnology ETF (IBB)
  • X
    S&P 500 Index (SPX)

or Cancel Already have a watchlist? Log In

By Tomi Kilgore

Shares of Idera Pharmaceuticals Inc. /zigman2/quotes/204152830/composite IDRA +31.77% plummeted 63.3% in active trading to pace all premarket decliners, after the immunotherapy company said the ILLUMINATE-301 pivotal registration trial of its treatment of patients with anti-PD-1 refractory advanced melanoma failed to meet its primary endpoint of objective response rate. Trading volume spiked to 6.0 million shares ahead of the open, compared with the full-day average of about 1.1 million shares over the past 30 days. The company said it is evaluating its next steps regarding continuation of the trial, toward its endpoint of overall survival. "We are surprised and disappointed that the response data from ILLUMINATE-301 do not lead us to an accelerated path to a new and much-needed treatment option for these patients," said Chief Executive Vincent Milano. J.P. Morgan analyst Matthew Bannon followed by downgrading Idera to neutral from overweight, saying the trial results has led to "significantly more uncertainty on several fronts." Through Thursday, the stock had rallied 22.6% over the past three months, while the iShares Nasdaq Biotechnology ETF /zigman2/quotes/206189322/composite IBB +1.13% has slipped 1.6% and the S&P 500 /zigman2/quotes/210599714/realtime SPX +0.31% has gained 5.6%.

US : U.S.: Nasdaq
$ 0.83
+0.20 +31.77%
Volume: 18.80M
Dec. 8, 2021 4:00p
P/E Ratio
Dividend Yield
Market Cap
$33.26 million
Rev. per Employee
US : U.S.: Nasdaq
$ 152.68
+1.71 +1.13%
Volume: 2.22M
Dec. 8, 2021 4:00p
+14.46 +0.31%
Volume: 2.16B
Dec. 8, 2021 4:59p

This Story has 0 Comments
Be the first to comment
More News In

Story Conversation

Commenting FAQs »

Partner Center

Link to MarketWatch's Slice.